FDA Approves Amgen's Biosimilar for Multiple Inflammatory Diseases, Including Psoriasis

The FDA has approved Wezlana (ustekinumab-auub) as an interchangeable biosimilar to Stelara (ustekinumab) for the treatment of multiple inflammatory diseases, including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. This approval provides additional safe and effective treatment options for patients managing these conditions and has the potential to increase access to medication at potentially lower costs. Wezlana has been shown to be highly similar to Stelara in terms of safety and effectiveness, and it may be substituted for the reference product without consulting the prescriber, similar to how generic drugs are substituted for brand name drugs.